Various Challenges and Opportunities in Oral Delivery of Anticancer Drugs

Main Article Content

Neha Kumari

Abstract

Oncology is that area of medicine where patients are usually treated intravenously. Researchers are trying to find alternative drug delivery methods of anticancer drugs due to the pain associated with conventional drug delivery methods. Studies estimate that a majority of patients (up to 89%) prefer oral anticancer medications to traditional IV fluid or injection therapies when available. Better patient compliance, tolerability, reduced cost; greatest safety and possible increased efficacy are the main reasons for increased attention towards oral delivery of anti-cancer drugs. But oral bioavailability of this class is limited because of its idiosyncratic physicochemical properties and biological barriers such as pre-systemic metabolism and gastrointestinal instability. The various challenges to oral delivery of anticancer drugs are discussed extensively in this paper including peculiar physicochemical properties, biological barriers and adverse drug-drug interactions. Further, the emerging innovations in addressing the challenges to oral delivery of anticancer drugs are discussed. These mainly include absorption enhancers and nanocarriers based drug delivery systems.

Keywords:
Patient compatibility, oral drug delivery, anticancer, absorption enhancer, nanocarriers.

Article Details

How to Cite
Kumari, N. (2019). Various Challenges and Opportunities in Oral Delivery of Anticancer Drugs. Journal of Advances in Medical and Pharmaceutical Sciences, 21(4), 1-18. https://doi.org/10.9734/jamps/2019/v21i430144
Section
Review Article

References

Banna GL, Collovà E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, et al. Anticancer oral therapy: Emerging related issues. Cancer Treat Rev. 2010;36:595–605.
Available:https://doi.org/10.1016/j.ctrv.2010.04.005

Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66. Available:https://doi.org/10.3322/caac.20004

Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer. 2005;5:161–71.
Available:https://doi.org/10.1038/nrc1566

Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.
Available:https://doi.org/10.1200/JCO.1997.15.1.110

Kuppens IELM, Bosch TM, Van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, et al. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemother Pharmacol. 2005;55: 72–8. Available:https://doi.org/10.1007/s00280-004-0864-4

Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 2006;23:1243–50.
Available:https://doi.org/10.1007/s11095-006-0022-2

Koolen SLW, Beijnen JH, Schellens JHM. Intravenous-to-oral switch in anticancer chemotherapy: A focus on docetaxel and paclitaxel. Clin Pharmacol Ther. 2010;87: 126–9. Available:https://doi.org/10.1038/clpt.2009.233

Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M, et al. Bioactivation of capecitabine in human liver: Involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metab Dispos. 2004;32:762–7.
Available:https://doi.org/10.1124/dmd.32.7.762

Choi JS, Jo BW. Enhanced paclitaxel bioavailability after oral administration of pegylated paclitaxel prodrug for oral delivery in rats. Int J Pharm. 2004;280: 221–7. Available:https://doi.org/10.1016/j.ijpharm.2004.05.014

Fayad W, Rickardson L, Haglund C, Olofsson MH, D’Arcy P, Larsson R, et al. Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties. Chem Biol Drug Des. 2011;78:547–57.
Available:https://doi.org/10.1111/j.1747-0285.2011.01170.x

Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MNV. Design of biodegradable nanoparticles for oral delivery of doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2009; 26:492–501. Available:https://doi.org/10.1007/s11095-008-9763-4

Gambhire VM, Salunkhe SM, Gambhire MS. Atorvastatin-loaded lipid nanoparticles: antitumor activity studies on MCF-7 breast cancer cells. vol. 44. Taylor & Francis; 2018.
Available:https://doi.org/10.1080/03639045.2018.1492605

Babu NJ, Sanphui P, Nangia A. Crystal Engineering of Stable Temozolomide Cocrystals. 2012:1–13.
Available:https://doi.org/10.1002/asia.201200205

Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: Challenges and opportunities. J Control Release. 2013;170:15–40.
Available:https://doi.org/10.1016/j.jconrel.2013.04.020

Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MNVR. PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res. 2009;26:2495–503.
Available:https://doi.org/10.1007/s11095-009-9965-4

Porat D, Dahan A. Active intestinal drug absorption and the solubility-permeability interplay. vol. 537. Elsevier B.V.; 2018.
Available:https://doi.org/10.1016/j.ijpharm.2017.10.058

Aulton ME. Chapter 25 Granulation. Pharm Sci Dos Form Des. 2001:364–78.
Available:https://doi.org/10.1016/0168-3659(89)90050-3

Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents. Clin Pharmacokinet. 2004;43: 1127–56. Available:https://doi.org/10.2165/00003088-200443150-00005

Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev. 1997;27:99–127.
Available:https://doi.org/10.1016/S0169-409X(97)00039-2

Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today. 2009; 14:1067–74. Available:https://doi.org/10.1016/j.drudis.2009.07.010

Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res. 2008;25:500–11.
Available:https://doi.org/10.1007/s11095-007-9347-8

Chen C, Zhou J, Ji C. Quercetin: A potential drug to reverse multidrug resistance. Life Sci. 2010;87:333–8.
Available:https://doi.org/10.1016/j.lfs.2010.07.004

Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm. 2006;313:144–9.
Available:https://doi.org/10.1016/j.ijpharm.2006.01.028

Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, pluronic p85, and vitamin e d-a-tocopheryl polyethylene glycol 1000 succinate on p-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS J. 2002; 4.

Ashiru-Oredope DAI, Patel N, Forbes B, Patel R, Basit AW. The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers. Int J Pharm. 2011;409:164–8.
Available:https://doi.org/10.1016/j.ijpharm.2011.02.059

qbal J, Hombach J, Matuszczak B, Bernkop-Schnürch A. Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J Control Release. 2010;147:62–9.
Available:https://doi.org/10.1016/j.jconrel.2010.06.023

Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci. 2002;91:1980–90.
Available:https://doi.org/10.1002/jps.10175

Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release. 2006;111:41–6. Available:https://doi.org/10.1016/j.jconrel.2005.11.011

Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16:237–46.
Available:https://doi.org/10.1016/S0928-0987(02)00055-6

Sha X, Yan G, Wu Y, Li J, Fang X. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci. 2005;24:477–86. Available:https://doi.org/10.1016/j.ejps.2005.01.001

Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. Effect of excipients on breast cancer resistance protein substrate uptake activity. J Control Release. 2007;124:1–5.
Available:https://doi.org/10.1016/j.jconrel.2007.08.021

Upadhyay AK, Singh S, Chhipa RR, Vijayakumar MV, Ajay AK, Bhat MK. Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: Involvement of Akt, NF-κB and Bcl-2. Toxicol Appl Pharmacol. 2006;216:177–85.
Available:https://doi.org/10.1016/j.taap.2006.05.009

Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, et al. Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci. 2009;38:405–13.
Available:https://doi.org/10.1016/j.ejps.2009.09.010

Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine. 2010;5: 287–306. Available:https://doi.org/10.2217/nnm.09.110

Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61:158–71.
Available:https://doi.org/10.1016/j.addr.2008.11.002

Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta - Biomembr. 2009;1788:892–910.
Available:https://doi.org/10.1016/j.bbamem.2008.09.016

Roger E, Lagarce F, Garcion E, Benoit JP. Lipid nanocarriers improve paclitaxel transport throughout human intestinal epithelial cells by using vesicle-mediated transcytosis. J Control Release. 2009; 140:174–81. Available:https://doi.org/10.1016/j.jconrel.2009.08.010

Jain S, Valvi PU, Swarnakar NK, Thanki K. Gelatin coated hybrid lipid nanoparticles for oral delivery of Amphotericin B. Mol Pharm. 2012;9:2542–53.
Available:https://doi.org/10.1021/mp300320d

Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8:1407–24. Available:https://doi.org/10.1517/17425247.2011.604311

Jacobs C, Kayser O, Müller RH. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm. 2001;214:3–7. Available:https://doi.org/10.1016/S0378-5173(00)00622-0

Garnett MC. Targeted drug conjugates: Principles and progress. Adv Drug Deliv Rev. 2001;53:171–216.
Available:https://doi.org/10.1016/S0169-409X(01)00227-7

Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 2010;390:242–9. Available:https://doi.org/10.1016/j.ijpharm.2010.02.013

Jain AK, Swarnakar NK, Das M, Godugu C, Singh RP, Rao PR, et al. Augmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal model. Mol Pharm. 2011;8:1140–51.
Available:https://doi.org/10.1021/mp200011f

Jain AK, Swarnakar NK, Godugu C, Singh RP, Jain S. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials. 2011;32:503–15.
Available:https://doi.org/10.1016/j.biomaterials.2010.09.037

Rajpoot P, Bali V, Pathak K. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan. Int J Pharm. 2012;426:219–30.
Available:https://doi.org/10.1016/j.ijpharm.2012.01.027

Chen Y, Chen C, Zheng J, Chen Z, Shi Q, Liu H. Development of a solid supersaturatable self-emulsifying drug delivery system of docetaxel with improved dissolution and bioavailability. Biol Pharm Bull. 2011;34:278–86.
Available:https://doi.org/10.1248/bpb.34.278

Zhang T, Chen J, Zhang Y, Shen Q, Pan W. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur J Pharm Sci. 2011;43:174–9. Available:https://doi.org/10.1016/j.ejps.2011.04.005

Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: Nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30: 592–9.
Available:https://doi.org/10.1016/j.tips.2009.08.004